• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Tema GLP-1, Obesity & Cardiometabolic ETF (NQ: HRTS )

    34.91 -0.07 (-0.20%)
    Streaming Delayed Price Updated: 11:23 AM EDT, Aug 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,504
    Open 34.96
    Bid (Size) 34.85 (1)
    Ask (Size) 34.90 (9)
    Prev. Close 34.98
    Today's Range 34.91 - 35.39
    52wk Range 26.26 - 36.03
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
    Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. 
    Via Benzinga
    EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
    The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
    Via Benzinga
    Topics ETFs

    Performance

    YTD
    +13.88%
    +13.88%
    1 Month
    +1.72%
    +1.72%
    3 Month
    +9.37%
    +9.37%
    6 Month
    +4.55%
    +4.55%
    1 Year
    +31.12%
    +31.12%

    More News

    Read More
    What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
    Via Investor's Business Daily
    Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply
    Via Benzinga
    Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test
    Via Investor's Business Daily
    Healthcare ETFs For The Weight-Loss Drug Boom And Beyond
    Via Talk Markets
    Topics Artificial Intelligence ETFs
    Exposures Artificial Intelligence
    Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
    Via Investor's Business Daily
    Ozempic, Weygovy – Obesity And Heart Health Constitute A Major Market That Is Only Growing
    Via Benzinga
    Topics ETFs
    Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
    Via Benzinga
    EXCLUSIVE: Tema ETFs' Innovative Thematic Investing Approach Targets New Opportunities Beyond The Fads
    Via Benzinga
    Topics ETFs
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.